(Reuters Health)—Adults 50 years and older who take tumor necrosis factor inhibitors (TNFi’s) for a range of inflammatory disorders can receive effective protection from shingles with a live varicella zoster vaccine, a clinical trial suggests.1
Researchers randomized 617 participants receiving TNFi’s in a 1:1 ratio to receive either the Zostavax live varicella zoster vaccine or placebo. The study included individuals with a variety of different inflammatory conditions, including rheumatoid arthritis (57.6%) and psoriatic arthritis (24.1%).
After six weeks of follow-up, none of the participants in the intervention group experienced a case of vaccine-associated shingles or varicella infection. Similar proportions of patients who received the live vaccine (3.2%) and placebo (2.6%) experienced serious adverse events through six months of follow-up.
“The prohibition against live virus vaccines in patients receiving TNFi biologics may not be as inviolable as might have been thought,” says lead study author Jeffrey Curtis, MD, MS, MPH, of the Division of Clinical Immunology & Rheumatology at the University of Alabama, Birmingham.
“I wouldn’t extrapolate that to severely immunocompromised patients such as organ transplant patients, nor patients receiving certain drugs known to increase zoster risk, such as janus kinase inhibitors like Rinvoq or Xeljanz, but for people on cytokine inhibitors, this live virus vaccine would seem to be ok,” Dr. Curtis said by email.
The most commonly used TNFi medication in the study was adalimumab (32.7%), followed by infliximab (31.3%), etanercept (21.2%), golimumab (9.1%) and certolizumab (5.7%). Many patients were on concomitant therapies, including methotrexate (48.0%) and oral glucocorticoids (10.5%).
Researchers assessed both humoral and cellular immune responses by gpELISA and ELISpot (IFN-gamma), respectively. From baseline to six weeks after vaccination, participants in the intervention group had mean geometric fold rises of 1.33 percentage points and 1.39 percentage points, respectively.
Although the vaccine-induced immunogenicity responses were robust, the study also found that cell-mediated responses were variable and not sustained at one year after vaccination, according to the report in the Annals of Internal Medicine. This suggests people on TNFi’s may require evaluation for a booster vaccination, the researchers note.1
Beyond its small size, one limitation of the study is that it only enrolled people over 50 years old, and immune responses may be superior in younger individuals, the study team notes. Another limitation is that the analysis only focused on a single type of immunomodulation therapy.
“Concerns regarding the safety of vaccinations reflects label contraindication of live vaccines,” says Kim Papp, MD, a dermatologist at Probity Medical Research in Waterloo, Ontario, who wasn’t involved in the study.
